Human Kazal Type Serine Protease Inhibitor Domain Containing Protein 1 (KAZALD1) Protein

Catalogue No.:abx166238



SDS-PAGE analysis of recombinant Human Kazal Type Serine Protease Inhibitor Domain Containing Protein 1 Protein.

Human Kazal Type Serine Protease Inhibitor Domain Containing Protein 1 is a recombinant Human protein expressed in E. coli.

Target:	Kazal Type Serine Protease Inhibitor Domain Containing Protein 1 (KAZALD1)
Research Area:	Signal Transduction
Origin:	Human
Expression:	Recombinant
Tested Applications:	WB, SDS-PAGE
Host:	E. coli
Conjugation:	Unconjugated
Form:	Lyophilized
Activity:	Not tested
Purity:	> 90%
Reconstitution:	To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH_2O. If a lower concentration is required, dilute in 10 mM PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in 10 mM PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.
Storage:	Store at 2-8°C for up to one month. For long-term storage, store at -80°C. Avoid repeated freeze/thaw cycles.

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com

UniProt Primary AC: Q96I82 (UniProt, ExPASy)

Gene Symbol: KAZALD1

GeneID: 81621

OMIM: 609208

HGNC: 25460

KEGG: hsa:81621

Ensembl: ENSG00000107821

String: 9606.ENSP00000359219

Molecular Weight: Calculated MW: 33.7 kDa
Observed MW (SDS-PAGE): 37 kDa
Possible reasons why the actual band size differs from the predicted band size:
1. Splice variants. Alternative splicing may create different sized proteins from the same gene.
2. Relative charge. The composition of amino acids may affect the charge of the protein.
3. Post-translational modification. Phosphorylation, glycoslyation, methylation etc. may affect the band size.
4. Post-translational cleavage. Many proteins are synthesised as pro-proteins, and then cleaved to give the active form.
5. Polymerisation of the target protein. Dimerisation, multimerisation etc. will increase the band size observed.

Sequence Fragment: Arg31-Tyr304

Sequence: RPSPGPDYLR RGWMRLLAEG EGCAPCRPEE CAAPRGCLAG RVRDACGCCW ECANLEGQLC DLDPSAHFYG HCGEQLECRL DTGGDLSRGE VPEPLCACRS QSPLCGSDGH TYSQICRLQE AARARPDANL TVAHPGPCES GPQIVSHPYD TWNVTGQDVI FGCEVFAYPM ASIEWRKDGL DIQLPGDDPH ISVQFRGGPQ RFEVTGWLQI QAVRPSDEGT YRCLGRNALG QVEAPASLTV LTPDQLNSTG IPQLRSLNLV PEEEAESEEN DDYY

Tag: N-terminal His tag

Buffer: Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 5% Trehalose.

Concentration: Prior to lyophilization: 500 µg/ml

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com